Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures
Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.
SLNOstock declinesecurities class action






